Table 6.
Estimated median survival for each group
| Estimated median survival (m p) | |||
|---|---|---|---|
| Group | Total (range) | Resected (range) | Unresected (range) |
| Total |
16.7 (9.4–32.5) (n = 33) |
24.24 (11.7–47.4) (n = 19) |
9.81 (7.1–17) (n = 16) |
| Resectable |
17.76 (9.4–27.2) (n = 14) |
25.29 (11.7–34) (n = 7) |
8.82 (7.1–11) (n = 6) |
| Unresectable |
16.2 (10.6–32.5) (n = 17) |
21.8 (15–32) (n = 9) |
12.16 (8.7–17) (n = 7) |
| Gemcitabine monotherapy |
19.18 (10.6–25) (n = 4) |
34 (34) (n = 1) |
7.1 (7.1) (n = 1) |
| Other regimens monotherapy |
14.77 (11.3–17.3) (n = 3) |
24.12 (15–32) (n = 4) |
9.73 (8.7–11) (n = 3) |
| Combination therapy |
16.87 (9.4–32.5) (n = 24) |
22.71 (11.7–47.4) (n = 13) |
10.9 (8.5–17) (n = 11) |
| Gemcitabine‐based chemo |
18.36 (10.6–32.5) (n = 24) |
26.21 (16.3–47.4) (n = 12) |
10.15 (7.1–17) (n = 10) |
| Non‐gemcitabine‐based chemo |
12.93 (9.4–17.3) (n = 7) |
19.21 (11.7–32) (n = 6) |
9.23 (8.5–11) (n = 5) |
| Chemotherapy |
16.8 (13–27.2) (n = 8) |
24.33 (16.3–34.7) (n = 5) |
10.7 (8.6–13.2) (n = 5) |
| Chemo + radiotherapy |
16.73 (9.4–32.5) (n = 24) |
24.21 (11.7–47.4) (n = 14) |
9.47 (7.1–13) (n = 11) |